The sNDA is supported by data from the ASSERT study, which included patients less than 17 years old with genetically confirmed Alagille syndrome.
Your search for Odevixibat returned 3 results
Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor.
Bylvay is an oral reversible inhibitor of the ileal bile acid transporter.